Scott Megaffin

Scott Megaffin currently serves as the Chief Executive Officer and Board Member of Adiso Therapeutics, leading a dedicated team focused on developing innovative therapies for inflammatory diseases since January 2022. Previously, Scott was a Member of the Board of Directors and former Chief Executive Officer at Adastra Pharmaceuticals, where guidance led to a successful transaction with Cothera Bioscience in 2021. Other notable positions include President of Churchill Pharmaceuticals, Senior Vice President at Onconova, and multiple leadership roles at Cephalon, Adolor, Schering-Plough, Yamanouchi Pharma America, Pharmacia/Pfizer, and Bristol-Myers Squibb, demonstrating extensive experience in corporate finance, marketing, and commercial development within the biopharmaceutical and oncology sectors. Scott holds a Bachelor of Science in Biology from Pittsburg State University.